Royalty Pharma aims to grow by buying slices of drug sales, and the big twist is that it may be getting leaner while finding new deal flow as drug research expands worldwide. The upside comes from locking in more large royalty deals, but results can swing if a few key drugs stumble, rules change, or cheaper copycats arrive sooner than expected.Read more
Royalty Pharma makes money by buying a slice of future sales from successful medicines, but growing pressure to lower drug prices and faster copycat competition could shrink those payouts. See why higher borrowing costs and tougher deal competition may limit new growth, even as new partnerships and drug launches offer a path to keep revenue expanding.Read more
Royalty Pharma bets on a wave of new medicines by funding drug makers in exchange for a cut of future sales, and it aims to boost returns by recycling steady cash into new deals while buying back shares. The big watch-outs are legal fights over key payouts, drug-price policy changes, and the risk that too much cash depends on a small handful of blockbuster drugs.Read more
No trending discussion available.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
